219 related articles for article (PubMed ID: 16802706)
1. Canavan disease: studies on the knockout mouse.
Matalon R; Michals-Matalon K; Surendran S; Tyring SK
Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
[TBL] [Abstract][Full Text] [Related]
2. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
3. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
4. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease.
Surendran S; Rady PL; Michals-Matalon K; Quast MJ; Rassin DK; Campbell GA; Ezell EL; Wei J; Tyring SK; Szucs S; Matalon R
Brain Res Bull; 2003 Aug; 61(4):427-35. PubMed ID: 12909286
[TBL] [Abstract][Full Text] [Related]
5. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of Canavan's disease: from human to mouse.
Surendran S; Matalon KM; Tyring SK; Matalon R
J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
9. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
10. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
11. Mental retardation and hypotonia seen in the knock out mouse for Canavan disease is not due to succinate semialdehyde dehydrogenase deficiency.
Surendran S; Ezell EL; Quast MJ; Wei J; Tyring SK; Michals-Matalon K; Matalon R
Neurosci Lett; 2004 Mar; 358(1):29-32. PubMed ID: 15016427
[TBL] [Abstract][Full Text] [Related]
12. Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease.
Surendran S; Shihabuddin LS; Clarke J; Taksir TV; Stewart GR; Parsons G; Yang W; Tyring SK; Michals-Matalon K; Matalon R
Brain Res Dev Brain Res; 2004 Oct; 153(1):19-27. PubMed ID: 15464214
[TBL] [Abstract][Full Text] [Related]
13. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
14. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
15. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
16. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
17. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse.
Surendran S; Campbell GA; Tyring SK; Matalon R
Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967
[TBL] [Abstract][Full Text] [Related]
18. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
19. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.
Matalon RM; Michals-Matalon K
Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428
[TBL] [Abstract][Full Text] [Related]
20. Aspartoacylase gene knockout in the mouse: impact on reproduction.
Surendran S; Szucs S; Tyring SK; Matalon R
Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
